1.
J Nephrol
; 35(2): 653-656, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33616856
RESUMO
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.